Research
Hormonal
SGLT2 inhibitors reduce blood pressure and body weight in patients with Type 2 Diabetes.
SGLT2 inhibitors can help you lose a small amount of weight (about 1.7 kg or 2.4%) and lower your blood pressure. This is achieved through osmotic diuresis and reduced body fat mass. These effects contribute to overall cardiovascular and renal health.
GoodSupportsHIGH confidence
SGLT2 inhibitors exert multiple beneficial effects, including reductions in body weight and serum uric acid (SUA) as well as BP lowering and attenuation of glomerular hyperfiltration, which are likely linked to glycosuria-accompanied natriuresis.
Why this rating
Based on meta-analyses and clinical trials.
Source
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
Erik J.M. van Bommel et al. · Clinical Journal of the American Society of Nephrology · 2017
DOI 10.2215/cjn.06080616
narrative_reviewCited 219×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors (specifically empagliflozin) reduce major adverse cardiovascular events (MACE) and cardiovascular death in patients with Type 2 Diabetes and established cardiovascular disease.Strong
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) improve glycemic control in type 2 diabetes by blocking glucose reabsorption in the renal proximal tubule, inducing glycosuria.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →